INSUBCONTINENT EXCLUSIVE:
AmphoTLC is a critical drug to treat Mucormycosis or Black Fungus in India.Shares of Cadila Healthcare rose as much as 1.72 per cent to hit
an intraday high of Rs 633.20 after it informed exchanges that Zydus Cadila has entered into an agreement with TLC, a Taiwan-based
clinical-stage, specialty pharmaceutical company for marketing Mucormycosis or Black Fungus drug in the country.Zydus Cadila signed a
license supply and commercialization agreement to commercialize AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India."AmphoTLC is
a critical drug to treat Mucormycosis or Black Fungus in India
Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize
AmphoTLC in India," Cadila Healthcare said in a press release."AmphoTLC is the first and only complex generic drug to have achieved
bioequivalence to Gilead's AmBisome, proving its sameness to the safest form of amphotericin B in the world
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage,"
Cadila Healthcare added.Mucormycosis is a serious fungal infection also known as black fungus, and COVID Associated Mucormycosis is a
life-threatening form of mucormycosis which has emerged as a post-COVID complication, infecting about 30 per cent of COVID patients who are
diabetic or otherwise immunocompromised
If progression of the infection is not treated early, over 60% of patients could die, Cadila Healthcare said.AmphoTLC is a liposomal
amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis
The drug is approved in Taiwan and has been manufactured and sold by Yung Shin Pharmaceutical Industrial Co
The approval of AmphoTLC in India follows the conduct of comprehensive due diligence by regulators in India based on the numerous years of
development TLC has dedicated as well as its quality performance in the developed markets.The steep increase in price and the financial
burden it brings is forcing patients to opt for conventional amphotericin B, which is known for its nephrotoxicity, with many patients
having to discontinue usage due to renal toxicities, the Ahmedabad-based drug maker added.As of 1:47 pm, Cadila Healthcare shares traded 0.6
per cent higher at Rs 626, in-line with Sensex which was up 0.6 per cent.
